18 May Oculis Reports Positive Top-line Data from SKYGGN (Phase 2) Trial with OCS-01
Posted at 14:00h
in Press Release
...
07 May Oculis Announces Upcoming Presentation of SKYGGN Phase 2 Data at ASCRS
Posted at 14:00h
in Press Release
...
21 Apr Oculis Appoints Dr. Frédéric Pilotaz as VP of Technology & Pharmaceutical Sciences
Posted at 14:05h
in Non classé
...
03 Mar Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer
Posted at 14:00h
in Non classé
...
10 Feb Phase 2 Study Results of OCS-01: A Potential Topical Therapeutic for DME
Posted at 14:50h
in Non classé
...
22 Jan Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in DME
Posted at 12:20h
in Non classé
...
07 Oct Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Trial
Posted at 14:30h
in Non classé
...
17 Sep Oculis Announces Appointment of Leading Specialists to Scientific Advisory Board
Posted at 14:45h
in Non classé
...
16 May Why a pharma investor quit his day job to follow a vision (Guest interview)
Posted at 17:30h
in Non classé
...
04 Jan Oculis Expands Portfolio with a Novel Phase II-stage Anti-TNF alpha Antibody Fragment
Posted at 16:24h
in Non classé
...